Compare
Bionano Genomics, Inc. vs Precipio, Inc. vs Seer, Inc. vs 908 Devices Inc.
| Latest fiscal year | Bionano Genomics, Inc. BNGO | Precipio, Inc. PRPO | Seer, Inc. SEER | 908 Devices Inc. MASS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $28.51M | $24.05M | $16.58M | $56.20M |
| Revenue growth (YoY) | -7.4% | +29.8% | +17.0% | +17.7% |
| Gross margin | 46.3% (computed) | 44.5% | 51.1% | 50.6% |
| Operating margin | -116.9% | -5.0% | -470.5% | -70.1% |
| Net margin | -92.6% | -1.5% | -444.0% | 34.7% |
| Net income | -$26.39M | -$363.0K | -$73.60M | $19.49M |
| EPS (Diluted) | -$4.85 | -$0.23 | n/a | $0.54 |
| Operating cash flow | -$16.34M | $685.0K | -$44.45M | -$23.69M |
| Free cash flow | n/a | $359.0K | -$46.24M | -$24.64M |
| Cash & equivalents | $2.99M | $2.65M | $47.28M | $70.52M |
| Total assets | $73.58M | $21.32M | $296.08M | $190.07M |
| Total liabilities | $29.16M | $6.76M | $36.78M | $46.37M |
| Shareholders' equity | $44.42M | $14.56M | $259.31M | $143.70M |
| Return on year-end equity | -59.4% | -2.5% | -28.4% | 13.6% |
| Shares outstanding | 10.74M | 1.78M | n/a | 36.32M |
Revenue, most recent five fiscal years
| Fiscal year | Bionano Genomics, Inc. | Precipio, Inc. | Seer, Inc. | 908 Devices Inc. |
|---|---|---|---|---|
| Latest | $28.51M Ended 2025-12-31 | $24.05M Ended 2025-12-31 | $16.58M Ended 2025-12-31 | $56.20M Ended 2025-12-31 |
| 1 year earlier | $30.78M Ended 2024-12-31 | $18.53M Ended 2024-12-31 | $14.17M Ended 2024-12-31 | $47.75M Ended 2024-12-31 |
| 2 years earlier | $36.12M Ended 2023-12-31 | $15.20M Ended 2023-12-31 | $16.66M Ended 2023-12-31 | $50.23M Ended 2023-12-31 |
| 3 years earlier | $27.80M Ended 2022-12-31 | $9.41M Ended 2022-12-31 | $15.49M Ended 2022-12-31 | $46.85M Ended 2022-12-31 |
| 4 years earlier | $17.98M Ended 2021-12-31 | $8.85M Ended 2021-12-31 | $6.62M Ended 2021-12-31 | $42.21M Ended 2021-12-31 |